RYTM Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of -49.65%. Rhythm Pharmaceuticals's return on equity of -208.96% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Rhythm Pharmaceuticals has a consensus price target of $72.82, signalling upside risk potential of 30.38%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.141, which suggesting that the stock is 114.099% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 29.98x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of -2357.27%. Rhythm Pharmaceuticals's return on equity of -208.96% beat Palatin Technologies's return on equity of --.

Rhythm Pharmaceuticals has a consensus price target of $72.82, signalling upside risk potential of 30.38%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Rhythm Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.141, which suggesting that the stock is 114.099% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Rhythm Pharmaceuticals's net income of -$43.6M is lower than Palatin Technologies's net income of -$7.8M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 29.98x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of 4.63%. Rhythm Pharmaceuticals's return on equity of -208.96% beat TG Therapeutics's return on equity of -8.4%.

Rhythm Pharmaceuticals has a consensus price target of $72.82, signalling upside risk potential of 30.38%. On the other hand TG Therapeutics has an analysts' consensus of -- which suggests that it could grow by 26.71%. Given that Rhythm Pharmaceuticals has higher upside potential than TG Therapeutics, analysts believe Rhythm Pharmaceuticals is more attractive than TG Therapeutics.

Rhythm Pharmaceuticals has a beta of 2.141, which suggesting that the stock is 114.099% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.248, suggesting its more volatile than the S&P 500 by 124.789%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are smaller than TG Therapeutics quarterly revenues of $83.9M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than TG Therapeutics's net income of $3.9M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 41.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 29.98x versus 18.90x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -131.25% compared to Rhythm Pharmaceuticals's net margin of -36.72%. Rhythm Pharmaceuticals's return on equity of -208.96% beat Voyager Therapeutics's return on equity of 9.12%.

Rhythm Pharmaceuticals has a consensus price target of $72.82, signalling upside risk potential of 30.38%. On the other hand Voyager Therapeutics has an analysts' consensus of -- which suggests that it could grow by 195.85%. Given that Voyager Therapeutics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Voyager Therapeutics is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.141, which suggesting that the stock is 114.099% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.374%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $33.3M, which are larger than Voyager Therapeutics quarterly revenues of $24.6M. Rhythm Pharmaceuticals's net income of -$43.6M is lower than Voyager Therapeutics's net income of -$9M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 8.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 29.98x versus 1.97x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.